Due to the enormous risks of Covid19, companies will have to process highly sensitive health data of employees. This situation generates lots of questions on how data protection compliance can be ensured in these exceptional
Tags :Ex-Featured
On April 6, 2020, Credit Suisse launched, and on April 9, 2020 successfully completed, its registered offering of Usd 1.5 bn aggregate principal amount of 2.800% fixed rate senior notes due 2022, and Usd 1.5 bn aggregate principal amount of 2.950% fixed rate senior
Covid-19 pandemic has produced an unprecedented global supply chain crisis, stemming from a lack of mapping and flexibility around the multiple layers of global supply chains and a lack of diversification in sourcing strategies.
A first delivery of 92 tons of protection equipment from Shanghai arrived at Geneva Airport on Monday 6 April, 2020. Schellenberg Wittmer is advising and offering support to the Geneva Chamber of Commerce, Industry and Services (CCIG) and
Santhera Pharmaceuticals Holding announced that it had entered into an equity-linked financing arrangement with IRIS (France) in the initial gross amount of up to CHF 12 m over 12 months
Staying at home and self-quarantine are our reality during these challenging times. However, there might be powers in solitude you might have not thought of.
Elmar Büth, General Counsel Supply Chain & Healthcare Business EMEA at 3M, unveils to Legalcommunity.ch how Covid-19 outbreak has changed his work, what are the main legal implications and how this crisis could shape
The worldwide supplier of high performance sensor solutions ams completed a capital increase by way of a rights offering raising gross proceeds of approximately CHF 1.75 billion.
In late March 2020, Credit Suisse Group launched the issuance of Usd 3 bn 4.194% fixed rate/floating rate senior callable notes due 2031 under its Us Senior Debt Program and the issuance of Eur 2 bn 3.250% fixed rate reset
Relief Therapeutics Holding announces the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, now a subsidiary of Sonnet BioTherapeutics Holdings
